Skip to main content
SpringerLink
Log in

Management of arrhythmias in pulmonary hypertension

  • Reviews
  • Published:
Journal of Interventional Cardiac Electrophysiology Aims and scope Submit manuscript

Abstract

Background

Pulmonary hypertension (PH) is a potentially devastating clinical condition with a poor long-term prognosis. Cardiac arrhythmias are frequent in PH, and pulmonary hypertensives are particularly susceptible to the adverse haemodynamic effects of heart rhythm disorders. However, arrhythmia management in PH patients can be more challenging than in the general population due to the particular physiological idiosyncrasies associated with the condition. Here, we summarise and appraise the data pertaining to multimodality treatment of cardiac arrhythmias in PH to help refine the management strategy for this vulnerable patient group.

Results

The majority of our understanding of the safety and effectiveness of different arrhythmia treatments in PH is based on observational and retrospective data. Rhythm control is the overall goal, and for atrial and ventricular tachyarrhythmias, referral for catheter ablation, ideally using electroanatomical mapping technology in specialist centres, is the preferable means of achieving this. Contradictory viewpoints are expounded regarding the safety of beta blocker use in PH, though in three small prospective clinical trials and at least six animal models they appear to be well-tolerated. Nevertheless, amiodarone remains the preferred pharmacological treatment. Direct current cardioversion can be carried out effectively to terminate tachyarrhythmias in both the emergency and elective setting, though mechanistic studies demonstrate a higher recurrence rate in PH patients. Individual reports and series suggest that device implantation may be technically challenging and associated with a higher complication rate due to anatomical distortion and chamber enlargement. Modulation of sympathetic input to the heart appears to reduce arrhythmia vulnerability in canine models of PH, and its clinical application in humans is a worthwhile area of further study.

Conclusion

Prompt restoration of sinus rhythm improves outcomes in PH, and at present, the most reliable and safest strategy for long-term rhythm control is amiodarone and, where possible, ablation. Reinforcement of the evidence base with randomised prospective trials is necessary. This would be particularly beneficial to clarify the role of atrial fibrillation ablation and the safety and efficacy of beta-blockers. In addition, a more comprehensive assessment of the vulnerability of PH patients to potentially fatal brady- and ventricular tachyarrhythmias may help guide recommendations for provision of primary prevention device therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Wijeratne DT, Lajkosz K, Brogly SB, Lougheed MD, Jiang L, Housin A, et al. Increasing incidence and prevalence of World Health Organization groups 1 to 4 pulmonary hypertension: a population-based cohort study in Ontario, Canada. Circ Cardiovasc Qual Outcomes. 2018;11(2):e003973.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Benza R, Miller D, Barst R, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from REVEAL. Chest. 2012;142:448–56. https://doi.org/10.1378/chest.11-1460.

    Article  PubMed  Google Scholar 

  3. Hyduk A, Croft JB, Ayala C, Zheng K, Zheng ZJ, Mensah GA. Pulmonary hypertension surveillance—United States, 1980–2002. MMWR Surveill Summ. 2005;54:1–28.

    PubMed  Google Scholar 

  4. Olsson KM, Nickel NP, Tongers J, Hoeper MM. Atrial flutter and fibrillation in patients with pulmonary hypertension. Int J Cardiol. 2013;167:2300–5. https://doi.org/10.1016/j.ijcard.2012.06.024.

    Article  PubMed  Google Scholar 

  5. Rajdev A, Garan H, Biviano A. Arrhythmias in pulmonary arterial hypertension. Prog Cardiovasc Dis. 2012;55(2):180–6. https://doi.org/10.1016/j.pcad.2012.06.002.

    Article  PubMed  Google Scholar 

  6. Wanamaker B, Cascino T, McLaughlin V, Oral H, Latchamsetty R, Siontis KC. Atrial arrhythmias in pulmonary hypertension: pathogenesis, prognosis and management. Arrhythm Electrophysiol Rev. 2018;7(1):43–8. https://doi.org/10.15420/aer.2018.3.2.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation Investigators. N Engl J Med. 2002;347(23):1825–33.

    Article  CAS  PubMed  Google Scholar 

  8. Rottlaender D, Motloch LJ, Schmidt D, Reda S, Larbig R, Wolny M, et al. Clinical impact of atrial fibrillation in patients with pulmonary hypertension. PLoS ONE. 2012;7(3):e33902.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119.

    Article  PubMed  Google Scholar 

  10. Tongers J, Schwerdtfeger B, Klein G, Kempf T, Schaefer A, Knapp JM, et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J. 2007;153(1):127–32.

    Article  PubMed  Google Scholar 

  11. Ruiz-Cano MJ, Gonzalez-Mansilla A, Escribano P, Delgado J, Arribas F, Torres J, et al. Clinical implications of supraventricular arrhythmias in patients with severe pulmonary arterial hypertension. Int J Cardiol. 2011;146(1):105–6. https://doi.org/10.1016/j.ijcard.2010.09.065S0167-5273(10)00780-1.

    Article  PubMed  Google Scholar 

  12. Wen L, Sun ML, An P, Jiang X, Sun K, Zheng L, et al. Frequency of supraventricular arrhythmias in patients with idiopathic pulmonary arterial hypertension. Am J Cardiol. 2014;114:1420–5. https://doi.org/10.1016/j.amjcard.2014.07.079.

    Article  PubMed  Google Scholar 

  13. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324(12):781–8.

    Article  CAS  PubMed  Google Scholar 

  14. Ciarka A, Doan V, Velez-Roa S, Naeije R, van de Borne P. Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010;181:1269–75. https://doi.org/10.1164/rccm.200912-1856OC.

    Article  PubMed  Google Scholar 

  15. Ishikawa M, Sato N, Asai K, Takano T, Mizuno K. Effects of a pure alpha/beta-adrenergic receptor blocker on monocrotaline-induced pulmonary arterial hypertension with right ventricular hypertrophy in rats. Circ J. 2009;73:2337–41.

    Article  CAS  PubMed  Google Scholar 

  16. Bogaard HJ, Natarajan R, Mizuno S, Abbate A, Chang PJ, Chau VQ, et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med. 2010;182:652–60. https://doi.org/10.1164/rccm.201003-0335OC.

    Article  CAS  PubMed  Google Scholar 

  17. Fowler ED, Drinkhill MJ, Norman R, Pervolaraki E, Stones R, Steer E, et al. Beta1-adrenoceptor antagonist, metoprolol attenuates cardiac myocyte Ca2+ handling dysfunction in rats with pulmonary artery hypertension. J Mol Cell Cardiol. 2018;120:74–83. https://doi.org/10.1016/j.yjmcc.2018.05.015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. de Man FS, Handoko ML, van Ballegoij JJ, Schalij I, Bogaards SJ, Postmus PE, et al. Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. Circ Heart Fail. 2012;5:97–105.

    Article  PubMed  CAS  Google Scholar 

  19. Andersen S, Schultz JG, Andersen A, Ringgaard S, Nielsen JM, Holmboe S, et al. Effects of bisoprolol and losartan treatment in the hypertrophic and failing right heart. J Card Fail. 2014;20:864–73. https://doi.org/10.1016/j.cardfail.2014.08.003.

    Article  CAS  PubMed  Google Scholar 

  20. Sun J, Cheng J, Ding X, Chi J, Yang J, Li W. β3 adrenergic receptor antagonist SR59230A exerts beneficial effects on right ventricular performance in monocrotaline-induced pulmonary arterial hypertension. Exp Ther Med. 2020;19(1):489–98.

    CAS  PubMed  Google Scholar 

  21. Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology. 2006;130:120–6. https://doi.org/10.1053/j.gastro.2005.10.013.

    Article  CAS  PubMed  Google Scholar 

  22. Peacock A, Ross K. Pulmonary hypertension: a contraindication to the use of {beta}-adrenoceptor blocking agents. Thorax. 2010;65:454–5. https://doi.org/10.1136/thx.2008.111955.

    Article  CAS  PubMed  Google Scholar 

  23. Bandyopadhyay D, Bajaj NS, Zein J, Minai OA, Dweik RA. Outcomes of β-blocker use in pulmonary arterial hypertension: a propensity-matched analysis. Eur Respir J. 2015;46:750–60. https://doi.org/10.1183/09031936.00215514.

    Article  CAS  PubMed  Google Scholar 

  24. Thenappan T, Roy SS, Duval S, Glassner-Kolmin C, Gomberg-Maitland M. β-blocker therapy is not associated with adverse outcomes in patients with pulmonary arterial hypertension: a propensity score analysis. Circ Heart Fail. 2014;7:903–10. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001429.

    Article  CAS  PubMed  Google Scholar 

  25. So PP-S, Davies RA, Chandy G, Stewart D, Beanlands RSB, Haddad H, et al. Usefulness of β-blocker therapy and outcomes in patients with pulmonary arterial hypertension. Am J Cardiol. 2012;109:1504–9.

    Article  CAS  PubMed  Google Scholar 

  26. Grinnan D, Bogaard HJ, Grizzard J, Van Tassell B, Abbate A, DeWilde C, et al. Treatment of group I pulmonary arterial hypertension with carvedilol is safe. Am J Respir Crit Care Med. 2014;189:1562–4. https://doi.org/10.1164/rccm.201311-2025LE.

    Article  PubMed  Google Scholar 

  27. Farha S, Saygin D, Park MM, et al. Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial. JCI Insight. 2(16):e95240. https://doi.org/10.1172/jci.insight.95240.

  28. van Campen JS, de Boer K, van de Veerdonk MC, van der Bruggen CE, Allaart CP, Raijmakers PG, et al. Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study. Eur Respir J. 2016;48:787–96. https://doi.org/10.1183/13993003.00090-2016.

    Article  PubMed  Google Scholar 

  29. Temple IP. Arrhythmias in pulmonary arterial hypertension. J Congenit Heart Dis. 2017;1:2.

    Article  Google Scholar 

  30. Sunderji R, Kanji Z, Gin K. Pulmonary effects of low dose amiodarone: a review of the risks and recommendations for surveillance. Can J Cardiol. 2000 Nov;16(11):1435–40.

    CAS  PubMed  Google Scholar 

  31. Goldschlager N, Epstein AE, Naccarelli GV, Olshansky B, Singh B, Collard HR, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007;4(9):1250–9.

    Article  PubMed  Google Scholar 

  32. Hernández Voth AR, Catalán JS, Benavides Mañas PD, Ávila Martínez RJ, Peñalver Paolini CL, Díaz de Atauri Rodríguez MJ. A 73-year-old man with interstitial lung disease due to dronedarone. Am J Respir Crit Care Med. 2012;186:201–2.

    Article  PubMed  Google Scholar 

  33. Stack S, Nguyen D-V, Casto A, Ahuja N. Diffuse alveolar damage in a patient receiving dronedarone. Chest. 2015;147:e131–3.

    Article  PubMed  Google Scholar 

  34. Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol. 2009;54(12):1089–95. https://doi.org/10.1016/j.jacc.2009.04.085.

    Article  CAS  PubMed  Google Scholar 

  35. Bernard EO, Schmid ER, Schmidlin D, Scharf C, Candinas R, Germann R. Ibutilide versus amiodarone in atrial fibrillation: a double-blinded, randomized study. Crit Care Med. 2003;31(4):1031–4. https://doi.org/10.1097/01.CCM.0000053555.78624.0F.

    Article  CAS  PubMed  Google Scholar 

  36. Nair M, George LK, Koshy SK. Safety and efficacy of ibutilide in cardioversion of atrial flutter and fibrillation. J Am Board Fam Med. 2011;24(1):86–92. https://doi.org/10.3122/jabfm.2011.01.080096.

    Article  PubMed  Google Scholar 

  37. Bianconi L, Castro A, Dinelli M, Alboni P, Pappalardo A, Richiardi E, et al. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. Eur Heart J. 2000;21(15):1265–73. https://doi.org/10.1053/euhj.1999.2039.

    Article  CAS  PubMed  Google Scholar 

  38. Qin D, Leef G, Alam MB, Rattan R, Munir MB, Patel D, et al. Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation. J Cardiol. 2016;67(5):471–6. https://doi.org/10.1016/j.jjcc.2015.07.001.

    Article  PubMed  Google Scholar 

  39. Shults NV, Rybka V, Suzuki YJ, Brelidze TI. Increased smooth muscle Kv11.1 channel expression in pulmonary hypertension and protective role of Kv11.1 channel blocker dofetilide. Am J Pathol. 2020;190(1):48–56. https://doi.org/10.1016/j.ajpath.2019.09.010.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Rich JD, Thenappan T, Freed B, Patel AR, Thisted RA, Childers R, et al. QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. Int J Cardiol. 2013;167(3):669–76. https://doi.org/10.1016/j.ijcard.2012.03.071.

    Article  PubMed  Google Scholar 

  41. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105–11.

    Article  CAS  PubMed  Google Scholar 

  42. Mercurio V, Peloquin G, Bourji KI, Diab N, Sato T, Enobun B, et al. Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors, and clinical impact. Pulm Circ. 2018;8:204589401876987.

    Article  CAS  Google Scholar 

  43. Medarov BI, Judson MA. The role of calcium channel blockers for the treatment of pulmonary arterial hypertension: How much do we actually know and how could they be positioned today? Respir Med. 2015;109:557–64.

    Article  PubMed  Google Scholar 

  44. Rich S, Seidlitz M, Dodin E, Osimani D, Judd D, Genthner D, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998;114(3):787–92.

    Article  CAS  PubMed  Google Scholar 

  45. Eshtehardi P, Mojadidi MK, Khosraviani K, Pamerla M, Zolty R. Effect of digoxin on mortality in patients with isolated right ventricular dysfunction secondary to severe pulmonary hypertension. J Am Coll Cardiol. 2014;63(12 Supplement):A750.

    Article  Google Scholar 

  46. Alajaji W, Baydoun A, Al-Kindi SG, Henry L, Hanna MA, Oliveira GH. Digoxin therapy for cor pulmonale: a systematic review. Int J Cardiol. 2016;223:320–4.

    Article  PubMed  Google Scholar 

  47. Te ALD, Chung F-P, Lin Y-J, Chen S-A. Irregular wide QRS complex tachycardia in a patient with pulmonary hypertension: what is the mechanism? HeartRhythm Case Rep. 2(1):63–6.

  48. Morgan JM, McCormack DG, Griffiths MJ, Morgan CJ, Barnes PJ, Evans TW. Adenosine as a vasodilator in primary pulmonary hypertension. Circulation. 1991;84(3):1145–9.

    Article  CAS  PubMed  Google Scholar 

  49. Schilling RJ. Cardioversion of atrial fibrillation: the use of antiarrhythmic drugs. Heart. 2010;96(5):333–8. https://doi.org/10.1136/hrt.2008.155812.

    Article  PubMed  Google Scholar 

  50. Van Gelder IC, Crijns HJ. Cardioversion of atrial fibrillation and subsequent maintenance of sinus rhythm. Pacing Clin Electrophysiol. 1997;20(10 Pt 2):2675–83.

    Article  PubMed  Google Scholar 

  51. Biffi M, Boriani G, Bartolotti M, Bacchi Reggiani L, Zannoli R, Branzi A. Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters. Heart. 2002;87(5):443–8. https://doi.org/10.1136/heart.87.5.443.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Medi C, Kalman JM, Ling L-H, et al. Atrial electrical and structural remodeling associated with longstanding pulmonary hypertension and right ventricular hypertrophy in humans. J Cardiovasc Electrophysiol. 2012;23:614–20.

    Article  PubMed  Google Scholar 

  53. Roca GQ, Campbell P, Claggett B, Solomon SD, Shah AM. Right atrial function in pulmonary arterial hypertension circulation: cardiovascular imaging. 2015;8:null

  54. Cioffi G, de Simone G, Mureddu G, Tarantini L, Stefenelli C. Right atrial size and function in patients with pulmonary hypertension associated with disorders of respiratory system or hypoxemia. Eur J Echocardiogr. 2007;8(5):322–31.

    Article  PubMed  Google Scholar 

  55. Bandorski D, Schmitt J, Kurzlechner C, Erkapic D, Hamm CW, Seeger W, et al. Electrophysiological studies in patients with pulmonary hypertension: a retrospective investigation. Biomed Res Int. 2014;2014:617565.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Showkathali R, Tayebjee MH, Grapsa J, Alzetani M, Nihoyannopoulos P, Howard LS, et al. Right atrial flutter isthmus ablation is feasible and results in acute clinical improvement in patients with persistent atrial flutter and severe pulmonary arterial hypertension. Int J Cardiol. 2011;149:279–80.

    Article  PubMed  Google Scholar 

  57. Luesebrink U, Fischer D, Gezgin F, Duncker D, Koenig T, Oswald H, et al. Ablation of typical right atrial flutter in patients with pulmonary hypertension. Heart Lung Circ. 2012;21:695–9.

    Article  PubMed  Google Scholar 

  58. Bradfield J, Shapiro S, Finch W, et al. Catheter ablation of typical atrial flutter in severe pulmonary hypertension. J Cardiovasc Electrophysiol. 2012;23:1185–90.

    Article  PubMed  Google Scholar 

  59. Matsuo S, Yamane T, Tokuda M, Date T, Hioki M, Narui R, et al. Prospective randomized comparison of a steerable versus a non-steerable sheath for typical atrial flutter ablation. Europace. 2010;12(3):402–9.

    Article  PubMed  Google Scholar 

  60. Morillo CA, Verma A, Connolly SJ, Kuck KH, Nair GM, Champagne J, et al. RAAFT-2 Investigators. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA. 2014;311(7):692–700.

    Article  CAS  PubMed  Google Scholar 

  61. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1261–74. https://doi.org/10.1001/jama.2019.0693.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Santangeli P, Zado ES, Hutchinson MD, Riley MP, Lin D, Frankel DS, et al. Prevalence and distribution of focal triggers in persistent and long-standing persistent atrial fibrillation. Heart Rhythm. 2016;13(2):374–82.

    Article  PubMed  Google Scholar 

  63. Anter E, Di Biase L, Contreras-Valdes FM, Gianni C, Mohanty S, Tschabrunn CM, et al. Atrial substrate and triggers of paroxysmal atrial fibrillation in patients with obstructive sleep apnea. Circ Arrhythm Electrophysiol. 2017;10(11).

  64. Zhang YQ, Zhang FL, Wang WW, Chen XH, Chen JH, Chen LL. The correlation of pulmonary arterial hypertension with late recurrence of paroxysmal atrial fibrillation after catheter ablation. J Thorac Dis. 2018;10(5):2789–94. https://doi.org/10.21037/jtd.2018.04.92.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Bandyopadhyay D, Devanabanda AR, Hajra A, Tummala R, Ghosh RK, Chakraborty S, et al. Impact of pulmonary hypertension in patients undergoing atrial fibrillation ablation: a nationwide study. Int J Cardiol Heart Vasc. 2019;23:100348.

    PubMed  PubMed Central  Google Scholar 

  66. McGinty PM, Smith TW, Rogers JH. Transseptal left heart catheterization and the incidence of persistent iatrogenic atrial septal defects. J Interv Cardiol. 2011;24(3):254–63. https://doi.org/10.1111/j.1540-8183.2011.00630.x.

    Article  PubMed  Google Scholar 

  67. Mugnai G, Sieira J, Ciconte G, Hervas MS, Irfan G, Saitoh Y, et al. One year incidence of atrial septal defect after pv isolation: a comparison between conventional radiofrequency and cryoballoon ablation. Pacing Clin Electrophysiol. 2015;38(9):1049–57.

    Article  PubMed  Google Scholar 

  68. Linhart M, Werner JT, Stöckigt F, Kohlmann AT, Lodde PC, Linneborn LPT, et al. High rate of persistent iatrogenic atrial septal defect after single transseptal puncture for cryoballoon pulmonary vein isolation. J Interv Card Electrophysiol. 2018;52(2):141–8. https://doi.org/10.1007/s10840-018-0352-0.

    Article  PubMed  Google Scholar 

  69. Sandoval J, Gaspar J, Peña H, Santos LE, Córdova J, del Valle K, et al. Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension. European Respiratory Journal. 2011;38:1343–8. https://doi.org/10.1183/09031936.00072210.

    Article  CAS  PubMed  Google Scholar 

  70. Pilkington SA, Taboada D, Martinez G. Pulmonary hypertension and its management in patients undergoing non-cardiac surgery. Anaesthesia. 2015;70(1):56–70. https://doi.org/10.1111/anae.12831.

    Article  CAS  PubMed  Google Scholar 

  71. Hoeper MM, Benza RL, Corris P, de Perrot M, Fadel E, Keogh AM, Kühn C, Savale L, Klepetko W. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur Respir J. 2018;1801906.

  72. Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, Goldschlager NF, Hamilton RM, Joglar JA, Kim RJ, Lee R, Marine JE, McLeod CJ, Oken KR, Patton KK, Pellegrini CN, Selzman KA, Thompson A, Varosy PD. 2018 ACC/AHA/HRS Guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay, J Am Coll Cardiol. 2018.

  73. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt O, Cleland J, Deharo J-C, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA).

  74. Reddy M, Boolani H, Duthuluru S, Reddy N, Williamson T, Spikes L, et al. Complications of implantable cardiac-defibrillator implantation in patients with pulmonary hypertension. J Am Coll Cardiol. 2012;59(13 Supplement):E708.

    Article  Google Scholar 

  75. Handoko ML, Lamberts RR, Redout EM, de Man FS, Boer C, Simonides WS, et al. Right ventricular pacing improves right heart function in experimental pulmonary arterial hypertension: a study in the isolated heart. Am J Physiol Heart Circ Physiol. 2009;297:H1752–9.

    Article  CAS  PubMed  Google Scholar 

  76. Hardziyenka M, Surie S, de Groot JR, de Bruin-Bon HACMR, Knops RE, Remmelink M, et al. Right ventricular pacing improves haemodynamics in right ventricular failure from pressure overload: an open observational proof-of-principle study in patients with chronic thromboembolic pulmonary hypertension. Europace. 2011;13:1753–9.

    Article  PubMed  Google Scholar 

  77. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation. 2004;110(10):1308–12.

    Article  PubMed  Google Scholar 

  78. Chen SL, Zhang FF, Xu J, Xie DJ, Zhou L, Nguyen T, et al. Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). J Am Coll Cardiol. 2013;62(12):1092–100. https://doi.org/10.1016/j.jacc.2013.05.075.

    Article  PubMed  Google Scholar 

  79. Zhang Y, Wang Z, Zhang Y, Wang W, Wang J, Gao M, et al. Efficacy of cardiac autonomic denervation for atrial fibrillation: a meta-analysis. J Cardiovasc Electrophysiol. 2012;23(6):592–600. https://doi.org/10.1111/j.1540-8167.2011.02270.x.

    Article  PubMed  Google Scholar 

  80. Katritsis DG, Pokushalov E, Romanov A, Giazitzoglou E, Siontis GC, Po SS, et al. Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial. J Am Coll Cardiol. 2013;62(24):2318–25.

    Article  PubMed  Google Scholar 

  81. Zhao Q, Deng H, Jiang X, Dai Z, Wang X, Wang X, et al. Effects of intrinsic and extrinsic cardiac nerves on atrial arrhythmia in experimental pulmonary artery hypertension. Hypertension. 2015;66(5):1042–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Royal Papworth Hospital, Cambridge Biomedical Campus, Cambridge, CB2 0AY, UK

    S. Ashwin Reddy, Bharat V. Khialani, Andrew A. Grace & Claire A. Martin

  2. Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0QQ, UK

    Sarah L. Nethercott

Authors
  1. S. Ashwin Reddy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah L. Nethercott
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bharat V. Khialani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrew A. Grace
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Claire A. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SAR: preparation of manuscript, conceptual design, and literature sourcing. Responsible for overall content

SLN and BVK: aided manuscript preparation and editing

AAG and CAM: aided conceptualisation of article

All authors read and approved the final manuscript.

Corresponding author

Correspondence to S. Ashwin Reddy.

Ethics declarations

Ethics approval

Not applicable.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reddy, S.A., Nethercott, S.L., Khialani, B.V. et al. Management of arrhythmias in pulmonary hypertension. J Interv Card Electrophysiol 62, 219–229 (2021). https://doi.org/10.1007/s10840-021-00988-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10840-021-00988-y

Keywords

Search

Navigation